Geron (GERN) Competitors $1.30 +0.04 (+2.78%) As of 01:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. ALKS, LGND, FOLD, BCRX, CLDX, DVAX, INVA, MNKD, NVAX, and OPKShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. Geron vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies Innoviva MannKind Novavax OPKO Health Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Do analysts rate GERN or ALKS? Geron presently has a consensus target price of $4.61, indicating a potential upside of 256.07%. Alkermes has a consensus target price of $40.92, indicating a potential upside of 41.19%. Given Geron's higher possible upside, equities research analysts plainly believe Geron is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has preferable earnings and valuation, GERN or ALKS? Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M10.71-$174.57M-$0.21-6.17Alkermes$1.56B3.07$367.07M$2.0913.87 Is GERN or ALKS more profitable? Alkermes has a net margin of 23.30% compared to Geron's net margin of -119.54%. Alkermes' return on equity of 27.52% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Geron-119.54% -47.86% -26.78% Alkermes 23.30%27.52%17.98% Which has more volatility and risk, GERN or ALKS? Geron has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Do institutionals and insiders believe in GERN or ALKS? 73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 7.4% of Geron shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer GERN or ALKS? In the previous week, Alkermes had 2 more articles in the media than Geron. MarketBeat recorded 12 mentions for Alkermes and 10 mentions for Geron. Alkermes' average media sentiment score of 1.12 beat Geron's score of 0.81 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlkermes beats Geron on 12 of the 16 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$824.81M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-6.1720.3528.6119.64Price / Sales10.71304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book2.827.718.185.63Net Income-$174.57M-$55.11M$3.23B$257.73M7 Day Performance-10.07%0.68%-0.25%0.07%1 Month Performance-16.45%8.22%5.40%8.32%1 Year Performance-74.05%-2.64%26.35%13.78% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron3.4153 of 5 stars$1.30+2.8%$4.61+256.1%-74.3%$824.81M$76.99M-6.1770News CoverageALKSAlkermes4.8362 of 5 stars$29.23+1.3%$40.00+36.8%+23.4%$4.82B$1.56B13.991,800News CoveragePositive NewsUpcoming EarningsAnalyst ForecastLGNDLigand Pharmaceuticals4.0438 of 5 stars$113.76-0.7%$146.14+28.5%+28.6%$2.19B$167.13M-15.9880FOLDAmicus Therapeutics4.0953 of 5 stars$6.05-0.8%$16.22+168.1%-44.4%$1.86B$528.29M-67.21480BCRXBioCryst Pharmaceuticals4.186 of 5 stars$8.76-2.0%$16.70+90.6%+21.4%$1.83B$450.71M-33.69530Analyst RevisionCLDXCelldex Therapeutics2.482 of 5 stars$20.94-4.8%$50.11+139.3%-42.2%$1.39B$7.56M-7.76150News CoverageAnalyst RevisionDVAXDynavax Technologies4.4396 of 5 stars$10.30+0.3%$24.00+133.0%-1.1%$1.24B$277.25M-19.81350INVAInnoviva4.0518 of 5 stars$18.91-1.6%$55.00+190.9%+18.5%$1.19B$369.84M-18.72100News CoverageAnalyst ForecastAnalyst RevisionGap UpMNKDMannKind2.726 of 5 stars$3.54-1.7%$10.33+191.9%-34.0%$1.08B$285.50M35.40400Positive NewsAnalyst ForecastGap UpNVAXNovavax4.3311 of 5 stars$6.61-2.8%$17.00+157.2%-54.5%$1.07B$682.16M2.491,990Positive NewsOPKOPKO Health4.1824 of 5 stars$1.34-1.5%$2.75+105.2%-7.0%$1.06B$713.10M-19.142,997Positive News Related Companies and Tools Related Companies ALKS Competitors LGND Competitors FOLD Competitors BCRX Competitors CLDX Competitors DVAX Competitors INVA Competitors MNKD Competitors NVAX Competitors OPK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
